Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introduction to the inaugural issue of Annals of Palliative Medicine.

Annals of palliative medicine·2015
Same author

Painful boney metastases.

Annals of palliative medicine·2015
Same author

Rapid onset opioids in palliative medicine.

Annals of palliative medicine·2015
Same author

Neuromodulation and palliative medicine.

Annals of palliative medicine·2015
Same author

Painful bone metastases - Can we do better?

Annals of palliative medicine·2015
Same author

Pathophysiology of nausea and vomiting in palliative medicine.

Annals of palliative medicine·2015

Related Experiment Videos

Proton pump inhibitors and pain.

Howard S Smith1, Reena Dhingra, Lori Ryckewaert

  • 1Albany Medical College, Department of Anesthesiology, Albany, NY 12208, USA. smithh@mail.amc.edu

Pain Physician
|November 26, 2009
PubMed
Summary

Proton pump inhibitors (PPIs) may reduce iron absorption, potentially causing Restless Legs Syndrome (RLS)-like symptoms in susceptible individuals. Further research is needed to confirm this link between PPIs, iron deficiency, and RLS symptoms.

Related Experiment Videos

Area of Science:

  • Gastroenterology and Neurology
  • Pharmacology and Physiology

Background:

  • Proton pump inhibitors (PPIs) are commonly used to reduce stomach acid.
  • Iron deficiency is frequently observed in patients with Restless Legs Syndrome (RLS).
  • PPIs may alter duodenal pH, potentially impacting gastrointestinal iron absorption.

Purpose of the Study:

  • To explore a potential correlation between PPI use and the development of RLS-like symptoms.
  • To investigate if PPIs could exacerbate or induce iron deficiency, leading to RLS symptoms.
  • To highlight the need for research into the association between PPIs, iron absorption, and RLS.

Main Methods:

  • This study is theoretical, based on existing knowledge of PPIs and RLS.
  • It reviews the known mechanisms of PPIs affecting gastrointestinal pH and iron absorption.
  • It examines the established link between iron deficiency and RLS prevalence.

Main Results:

  • PPIs may decrease gastrointestinal iron absorption due to altered duodenal pH.
  • Iron deficiency is a known factor in Restless Legs Syndrome.
  • A theoretical link suggests PPI-induced iron deficiency could manifest as RLS-like symptoms, including pain.

Conclusions:

  • There is a theoretical possibility that PPIs may contribute to RLS symptoms by impairing iron absorption.
  • Patients on PPIs developing iron deficiency might experience RLS-like symptoms.
  • Further clinical research is warranted to validate the association between PPIs, iron deficiency, and RLS.